How Has The Computer Vision in Glioblastoma Multiforme (GBM) Treatment Market Size Evolved In Recent Years?
The glioblastoma multiforme (gbm) treatment market has seen considerable growth due to a variety of factors.
• The market size of glioblastoma multiforme (GBM) treatment has experienced a significant escalation recently. The market, which is projected to swell from $2.48 billion in 2024 to $2.74 billion in 2025, boasts a compound annual growth rate (CAGR) of 10.2%.
This expansion during the historic phase is credited to factors such as a surge in occurrence and prevalence, advancements in diagnostic methods, clinical trials and research investments, cooperative endeavors and partnerships, and an enhanced comprehension of tumor biology.
What Can Be Expected from the Glioblastoma Multiforme (GBM) Treatment Market in the Coming Years?
The glioblastoma multiforme (gbm) treatment market is expected to maintain its strong growth trajectory in upcoming years.
• Growth is anticipated to accelerate in the glioblastoma multiforme (GBM) treatment market, reaching a worth of $4.1 billion by the year 2029, with a Compound Annual Growth Rate (CAGR) of 10.6%.
Enhanced understanding of genetic markers, advancements in precision medicine, the rise of immunotherapies, increased patient advocacy and awareness, alongside government support for unusual illnesses, can all be credited for this forecasted growth. Throughout the projection period, exploration of combined therapies, application of artificial intelligence in diagnosis and treatment scheduling, growing acceptance of immunotherapeutic methods, and the progress of medical tools and facilities all represent crucial trends.
What Are The Core Factors Supporting Growth In Glioblastoma Multiforme (GBM) Treatment Market?
The escalating occurrence of brain-related illnesses is anticipated to bolster the growth of the GBM treatment market in the future. These types of disorders pertain to any dysfunction in the brain, our nerves, and spinal cord. The rising incidence of conditions such as GBM can be attributed to several factors, including an aging population, weakened immune systems, overdiagnosis, exposure to ionizing radiation, air pollution, and more. This creates a strong demand for effective treatments to enhance individual health and wellness. For example, a 2022 report from the American Cancer Society, a US-based non-profit committed to cancer eradication, revealed that approximately 25,050 cases of malignant brain or spinal cord tumors were diagnosed in the US. Consequently, this growing prevalence of brain conditions is propelling the expansion of the GBM treatment marketplace.
How Are The Segments Defined Within The Global Glioblastoma Multiforme (GBM) Treatment Market?
The glioblastoma multiforme (GBM) treatment market covered in this report is segmented –
1) By Treatment: Surgery, Radiation Therapy, Chemotherapy, Targeted Therapy, Tumor Treating Field (TTF) Therapy, Immunotherapy
2) By Drug Class: Temozolomide, Bevacizumab, Lomustine, Carmustine Wafers, Other Drug Classes
3) By Route Of Administration: Oral, Parenteral, Other Route Of Administrations
4) By End-Use: Hospitals, Clinics, Ambulatory Surgical Centers
Subsegments:
1) By Surgery: Tumor Resection, Biopsy Procedures
2) By Radiation Therapy: External Beam Radiation Therapy (EBRT), Stereotactic Radiation Therapy
3) By Chemotherapy: Standard Chemotherapy, Combination Chemotherapy Regimens
4) By Targeted Therapy: EGFR Inhibitors, Other Targeted Agents
5) By Tumor Treating Field (TTF) Therapy: Device-Based TTF Treatment
6) By Immunotherapy: Checkpoint Inhibitors, Vaccine-Based Therapies
Pre-Book The Glioblastoma Multiforme (GBM) Treatment Global Market Report 2025 Report For Swift Delivery And Comprehensive Insights:
How Are New Trends Expected To Influence The Growth Of The Glioblastoma Multiforme (GBM) Treatment Market?
Leading market players are concentrating on creating innovative portable and wearable devices to maintain their market dominance. Such breakthroughs strive to provide users with improved functionality, simplicity, and comfort, addressing the increasing need for efficient and accessible healthcare offerings. For instance, in 2023, Novocure, an oncology firm based in Jersey, introduced Optune Gio, an FDA approved wearable and compact treatment system designed for patients newly diagnosed with glioblastoma (GBM). The device utilizes Tumor Treating Fields (TTFields), alternate electric fields designed to halt the division of cancer cells, thereby possibly prolonging the lifespan of patients. With a weight of only 2.7 pounds, Optune Gio is designed with comfort in mind, enabling patients to wear it while carrying out their everyday activities.
Who Are the Key Players in the Glioblastoma Multiforme (GBM) Treatment Market?
Major companies operating in the glioblastoma multiforme (GBM) treatment market include:
• Pfizer Inc.
• F. Hoffmann-La Roche AG
• Merck & Co. Inc.
• AbbVie Inc.
• Novartis AG
• AstraZeneca PLC
• Amgen Inc.
• Teva Pharmaceutical Industries Ltd.
• Sun Pharmaceutical Industries Limited
• Jazz Pharmaceuticals Inc.
• Sumitomo Dainippon Pharma Oncology Inc.
• Varian Medical Systems Inc.
• Amneal Pharmaceuticals Inc.
• Elekta AB
• ANI Pharmaceuticals Inc.
• Accord Healthcare Limited
• The Eckert & Ziegler Group
• Loxo Oncology Inc.
• Karyopharm Therapeutics Inc.
• Celon Laboratories Pvt. Ltd.
• EnGeneIC Ltd.
• Zydus Pharmaceuticals Inc.
• Genenta Science S.r.l.
• Cantex Pharmaceuticals Inc.
• Vascular Biogenics Ltd.
• Seelos Therapeutics Inc
• Angiochem Inc.
• Diffusion Pharmaceuticals Inc.
What Is The Most Dominant Region In The Glioblastoma Multiforme (GBM) Treatment Market?
North America was the largest region in the glioblastoma multiforme (GBM) treatment market share in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the glioblastoma multiforme (gbm) treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
